- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Roche Diagnostics, Redcliffe Labs collaborate for early Alzheimer's prediction
New Delhi: Redcliffe Labs has partnered with Roche Diagnostics India to offer a combination of Roche Diagnostics' biomarker testing with Redcliffe Labs genetic testing for early Alzheimer's prediction.
Through the collaboration, Redcliffe Labs will be the first to bring to India Roche Diagnostics' Elecsys ß-Amyloid (1-42) CSF II (cerebrospinal fluid), Elecsys Phospho-Tau (181P) CSF and Elecsys Total-Tau CSF immunoassays. Elecsys AD CSF tests are intended for use in adult patients with cognitive impairment to aid in the early diagnosis of Alzheimer's disease (AD) and to identify patients with mild cognitive impairment (MCI) who are at increased risk of cognitive decline.
Elecsys AD CSF assays can detect amyloid positivity, enhancing diagnostic accuracy and physician confidence. These in-vitro diagnostic immunoassays are for the measurement of ß-Amyloid (1–42), phospho-Tau, and total Tau protein concentrations in CSF of adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD) or other causes of dementia.
Mr. Dheeraj Jain, the Founder & Managing Director of Redcliffe Labs said "Alzheimer's has a significant adverse impact on public health, including incidence, mortality, morbidity, and associated costs of care. More than 5 million people in India alone suffer from dementia, with AD thought to account for 60% to 80% of cases. Currently, a considerable portion of AD diagnoses are made mainly on clinical symptoms, including cognitive tests, and many people are identified after their illness is extremely advanced. 50% to 75% of those who have dementia do not have an official MCI or AD diagnosis. Furthermore, 70 to 80 percent of AD diagnoses are correct when based solely on cognitive tests. This partnership between Redcliffe Labs and Roche Diagnostics will mark a significant turning point as, with the help of CSF immunoassays, the accuracy of an AD diagnosis is increased and the development of the disease can be assessed by doctors."
Mr. Narendra Varde, Managing Director, Roche Diagnostics India and Neighboring Markets said, "India currently faces a dual problem in terms of lack of effective diagnostic mechanisms and access to treatment for dementia and Alzheimer's disease. According to a 2020 report by the Alzheimer's and Related Disorders Society of India (ARDSI), an estimated 5.3 million people above the age of 60 have dementia in the country, and the burden of Alzheimer's is expected to increase in the coming years. The need of the hour is to ensure timely diagnosis and intervention. To bridge this need gap, I am excited to introduce the Elecsys CSF tests, which offers a standardised pre-analytical protocol for clinicians and labs to provide reliable, safe, and accurate identification of patients with Alzheimer's disease."
Ishaan Khanna, Director of Reproductive Medicine and Genetics, Redcliffe Labs, said "The availability of an Elecsys AD CSF test can potentially eliminate the need for time-consuming and expensive scans, which is great news for individuals and families concerned with the possibility of an Alzheimer's disease diagnosis. With the Elecsys AD CSF test, there is a new option that can typically be completed on the same day and can give doctors the same information regarding brain amyloid status without the radiation risk, to help determine if a patient's cognitive impairment is due to Alzheimer's disease."
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751